Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: A pilot study

British Journal of Haematology

Volumn 123, Issue 5, 2003, Pages 836-841

  Rosen, O ^a   Muller H J ^b   Gokbuget N ^c   Langer, W ^d   Peter, N ^e   Schwartz, S ^a   Hahling D ^f   Hartmann, F ^g   Ittel, T H ^h   Muck, R ⁱ   Rothmann, F ^j   Arnold, R ^a   Boos, J ^b   Hoelzer, D ^c,k  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d Ev Krankenhaus Essen Werden   (Germany)

^e CARL THIEM KLINIKUM   (Germany)

^f Klinikum Schwerin   (Germany)

^g SAARLAND UNIVERSITY   (Germany)

^h Klinikum Stralsund   (Germany)

ⁱ Departrnent of Oncology   (Germany)

^j KLINIKUM ERNST VON BERGMANN   (Germany)

^k UNIVERSITY HOSPITAL FRANKFURT   (Germany)

more..

Author keywords

Adult acute lymphoblastic leukaemia; Consolidation; Drug monitoring; Pegylated asparaginase; Pilot study

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL; ASPARAGINE; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLEEDING DISORDER; CANCER REGRESSION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPNEA; ENZYME ACTIVITY; HUMAN; LARYNX EDEMA; LIVER TOXICITY; MULTICENTER STUDY; PANCREAS DISEASE; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT; THROMBOEMBOLISM; URTICARIA;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; ASPARAGINE; BLOOD COAGULATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LIVER; MALE; METHOTREXATE; MIDDLE AGED; PILOT PROJECTS; REMISSION INDUCTION;

EID: 10744226317     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04707.x     Document Type: Article

References (25)

1. Abshire, T.C., Pollock, B.H., Billett, A.L., Bradley, P. & Buchanan, G.R. (2000) Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study. Blood, 96, 1709-1715.
2. Asselin, B.L., Whitin, J.C., Coppola, D.J., Rupp, I.P., Sallan, S.E. & Cohen, H.J. (1993) Comparative pharmacokinetic studies of three asparaginase preparations. Journal of Clinical Oncology, 11, 1780-1786.
3. Berg, S.L., Balis, P.M., McCully, C.L., Godwin, K.S. & Poplack, D.G. (1993) Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkey. Cancer Chemotherapy and Pharmacology, 32, 310-314.
4. Boos, J., Werber, G., Ahlke, E., Schulze-Westhoff, P., Nowak-Göttl, U., Würthwein, G., Verspohl, E.J., Ritter, J. & Jürgens, H. (1996) Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. European Journal of Cancer, 32, 1544-1550.
5. Capizzi, R.L. (1975) Improvement in the therapeutic index of methotrexate (NSC 109229) by Lasparaginase (NSC 109299). Cancer Chemotherapy Reports, 6, 37-41.
6. Capizzi, R.L. (1981) Asparaginase-methotrexate in combination chemotherapy: Schedule-dependent differential effects on normal versus neoplastic cells. Cancer Treatment Reports, 65, 115-121.
7. Capizzi, R.L. & Cheng, Y.C. (1981) Therapy of neoplasia with asparaginase. In: Enzymes as Drugs (ed. by J. Holcenberg & J. Roberts), pp. 1-24. Wiley, New York.
8. Dellinger, C.T. & Miale, T.D. (1976) Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia cultures. Cancer, 38, 1843-1846.
9. Evans, W.E., Tsiatis, A., Rivera, G., Murphy, S.B., Dahl, G.V., Denison, M., Crom, W.R., Barker, L.F. & Mauer, A.M. (1982) Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer, 49, 1378-1383.
10. Frankel, S.R., Kurtzberg, J., DeOleivera, D., Dodge, R., Peterson, B., Powell, B.L., Larson, R.A. & Schiffer, C.A. (1996) Toxicity and pharmacokinetics of PEG-asparaginase (PEG-asp) in newly diagnosed adult acute lymphoblastic leukemia (ALL): CALGB9511. Blood, 88(Suppl. 1/1), 669 (abstract).
11. Harris, R.E., McCallister, J.A., Provisor, D.S., Weetman, R.M. & Baehner, R.L. (1980) Methotrexate/L-asparaginase combination chemotherapy for patients with acute leukemia in relapse: a study of 36 children. Cancer, 46, 2004-2008.
12. Hudson, M.M., Dahl, G.V., Kalwinsky, D.K. & Pui, C.H. (1990) Methotrexate plus L-asparaginase. Cancer, 65, 2615-2618.
13. Koerholz, D., Brueck, M., Nuernberger, W., Juergens, H., Goebel, U. & Wahn, V. (1989) Chemical and immunological characteristics of four different L-asparaginase preparations. European Journal of Haematology, 42, 417-424.
14. Kurtzberg, J., Asselin, B., Poplack, D., Grebanier, A., Chen, R., Franklin, A., Scudiery, D. & Fisherman, J. (1993) Antibodies to asparaginase alter pharmacokinetics and decreases enzyme activity in patients on asparaginase therapy. Proceedings of the American Association for Cancer Research, 34, 304.
15. Lanvers, C., Vieira Pinheiro, J.P., Hempel, G., Würthwein, G. & Boos, J. (2002) Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum. Analytical Biochemistry, 309, 117-126.
16. Larson, R.A., Fretzin, M.H. & Dodge, R.K. (1998) Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia, 12, 660-665.
17. Lobel, J.S., O'Brien, R.T., McIntosh, S., Aspnes, G.T. & Capizzi, R.L. (1979) Methotrexate and asparaginase combination chemotherapy in refractory acute lymphoblastic leukemia of childhood. Cancer, 43, 1089-1094.
18. Müller, H.J., Loning, L., Horn, A., Schwabe. D., Gunkel, M., Schrappe, M., Von Schutz, V., Henze, G., Casimiro Da Palma. J., Ritter, J., Pinheiro, J.P., Winkelhorst, M. & Boos, J. (2000) Pegylated asparaginase (Oncaspar™) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. British Journal of Haematology, 110, 379-384.
19. Otten, J., Suciu, S. & Lutz, P. (1996) The importance of L-asparaginase (A'ASE) in the treatment of of acute lymphoblastic leukemia (ALL) in children: results of the EORTC 58881 randomized phase III trial showing greater efficiency ot Escherichia coli of (E. coli) as compared with Erwinia (ERW) A'ASE. Blood, 88(Suppl. 1), 669 (abstract).
20. Pinkel, D. & Woo, S. (1994) Prevention and treatment of meningeal leukemia in children. Blood, 84, 355-366.
21. Riccardi, R., Holcenberg, J.S., Glaubinger, D.X., Wood, J.H. & Poplack, D.G. (1981) L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Research, 41, 4554-4558.
22. Rizzari, C., Zucchetti, M., Conter, V., Diomede, L., Bruno, A., Gavazzi, L., Paganini, M., Sparano, P., Lo Nigro, L., Arico, M., Milani, M. & D'Incalci, M. (2000) L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Annals of Oncology, 11, 189-193.
23. Vadlamudi, S., Krisha, B., Reddy, V.V.S & Goldin, A. (1973) Schedule-dependent therapeutic synergism for L-asparaginase and methotrexate in leukemic (L5178Y) mice. Cancer Research, 33, 2014-2019.
24. Vieira Pinheiro, J.P., Ahlke, E., Nowak-Gottl, U., Hempel, G., Müller, H.J., Lumkemann, K., Schrappe, M., Rath, B., Fleischhack, G., Mann, G. & Boos, J. (1999) Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols. British Journal of Haematology, 104, 313-320.
25. Wolfrom, C., Hartmann, R., Fengler, R. & Henze, G. (1993) Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia. Journal of Clinical Oncology, 11, 827-833.